1763 (1763) Fair Value & Analysis

Healthcare · Market cap HK$5.7B

1 1763 1763 · HK

PriceHK$17.27

Fair ValueHK$24.70

Upside+43.0%

Quality52/100

Watch 1763 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$15.27 – HK$30.88

Fair value as of: Jul 2, 2026

From 16 valuation models · updated today

Share price −6.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$14.25 – HK$24.06 · fair‑value band HK$15.27 – HK$30.88 · the HK$17.27 price screens below the HK$24.70 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1763 (1763) currently trades at HK$17.27, while our model-based Fair Value estimate is HK$24.70 — implying the stock looks roughly 43.0% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1763 generated revenue of HK$7.2B at a net margin of 4.6%. Revenue declined 9.1% year over year. It earns a return on equity of 8.4%. Net debt stands at HK$134M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$7.2B

Revenue growth (YoY) -9.1%

Net margin 4.6%

Return on equity 8.4%

Free cash flow −HK$48.4M FY2025

P/E ratio 15.0

More key figures

Operating margin 13.3%

EPS (TTM) HK$0.5400

Dividend yield 1.8%

EPS growth (YoY) -38.4%

Net debt HK$134M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1763 reported revenue of HK$7.0B in FY2025 versus HK$5.1B in FY2021, a compound +8.0%/yr. Reported net income was HK$319M in FY2025, compounding −1.3%/yr from FY2021.

Revenue +8.0%/yr

FY21 HK$5.1B

FY22 HK$6.1B

FY23 HK$6.6B

FY24 HK$7.6B

FY25 HK$7.0B

Net income −1.3%/yr

FY21 HK$336M

FY22 HK$392M

FY23 HK$371M

FY24 HK$407M

FY25 HK$319M

Is 1763 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1763 (1763) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$24.70 versus a price of HK$17.27 — about +43% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1763?

Our model-based fair value for 1763 is HK$24.70 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$17.27.

What is the quality score of 1763?

1763 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1763 (1763)?

1763 reported trailing-twelve-month revenue of about HK$7.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1763?

The net profit margin of 1763 is about 4.6%, meaning it keeps roughly 4.6% of revenue as net income. Based on the latest reported figures.

Does 1763 pay a dividend?

1763 currently shows a dividend yield of about 1.75% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.